Floatz logo

Ipilimumab

Locally Advanced Renal Pelvis Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Locally Advanced Renal Pelvis Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
H. Lee Moffitt Cancer Center and Research Institute
Phase 3BB
Vinflunine
Dr Anders Ullén
Phase 2BB
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3B
Icrucumab
Eli Lilly and Company
Phase 2B
Docetaxel
Eli Lilly and Company
Phase 2B

View all 17 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →